EV3 reported yesterday that sales of Fox Hollow's atherectomy catheter were up 22% in Q209 versus Q109. Still, annualizing at less than $90 million which is only about half of what Fox Hollow did at their "peak" in 2007.

Investors will likely be looking very closely at what CSI reports for Q2 sales of the Diamondback compared to Q1. While the year over year comparison will likely be good, it is the sequential quarterly comparison that will show if "momentum" is improving or declining.

Should know the answer to that key question within a week or so.